aap Implantate AG

Business and Financial Review • Mar 29, 2013

News Details

Ad-hoc | 29 March 2013 19:12

aap Implantate AG: Closing of a development and supply agreement supports positive outlook for 2013

aap Implantate AG / Key word(s): Contract

29.03.2013 19:12

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

aap Implantate AG (XETRA: AAQ.DE) today closed an in the second quarter of
2012 signed development and supply agreement with a global medtech company.
The effectiveness of the agreement was depended on the achievement of
various conditions precedent, which came into effect today. The contract
relates to the development of a biomaterial and its mixing and application
device followed by the transfer of the know-how. When all of the milestones
of the development agreement are reached, aap will receive payments
totalling EUR 6.9 million (based on current exchange rates). The following
milestone payments will be booked in the first quarter of 2013: a EUR 2.8
million upfront-payment is to be presented as 'other operating income', two
other milestone payments totalling EUR 1.5 million will be accounted for as
'sales'.
The supply agreement has a term of 24 months with an option for renewal. At
least EUR 1.4 million in sales arising from the supply agreement is
anticipated in 2013.
The conclusion of the development and supply agreement supports our
positive outlook for 2013. For now, we reaffirm our forecast for 2013:
Sales and EBITDA growth to be at least 10% and 15% respectively.

This release contains forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. Many factors could cause the actual results, performance or
achievements of aap to be materially different from those that may be
expressed or implied by such statements. These factors include those
discussed in aap's public reports. Forward-looking statements therefore
speak only as of the date they are made. aap does not assume any obligation
to update the forward-looking statements contained in this release or to
conform them to future events or developments.

Contact:
Contact:
aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099
Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290;
m.heydrich@aap.de

29.03.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart

End of Announcement DGAP News-Service

---